Search - tctmd.com

Displaying 21 - 40 of 2286

Sort: Relevancy | Date

Patients With Obesity Get Biggest Benefit from Evolocumab: FOURIER

News Daily News

Patients With Obesity Get Biggest Benefit from Evolocumab: FOURIER

Michael O'Riordan

December 12, 2025

STAR Trial Gives Insight Into Two-Stage CTO PCI in Complex Patients

News Daily News

STAR Trial Gives Insight Into Two-Stage CTO PCI in Complex Patients

Yael L. Maxwell

December 05, 2025

November 2025 Dispatch for the CV Team

News Opinion CV Team Dispatch

November 2025 Dispatch for the CV Team

November 24, 2025

Long-Awaited CREST-2 Results Bolster Stents for Asymptomatic Carotid Stenosis

News Daily News

Long-Awaited CREST-2 Results Bolster Stents for Asymptomatic Carotid Stenosis

November 21, 2025

Dig Deeper When Dealing With Nonobstructive CAD, AHA Urges

News Daily News

Dig Deeper When Dealing With Nonobstructive CAD, AHA Urges

November 21, 2025

Sham-Controlled Trial, and More, Bolster Pulsed-Field Ablation for AF

News Conference News AHA 2025

Sham-Controlled Trial, and More, Bolster Pulsed-Field Ablation for AF

November 17, 2025

Stress CMR Facilitates Diagnosis, Targeted Care in ANOCA: CorCMR

News Conference News AHA 2025

Stress CMR Facilitates Diagnosis, Targeted Care in ANOCA: CorCMR

November 14, 2025

POLY-HF: Polypill Pays Dividends in Patients With HFrEF

News Conference News AHA 2025

POLY-HF: Polypill Pays Dividends in Patients With HFrEF

November 14, 2025

Déjà Vu All Over Again? Results of Intracoronary Stem Cell Study Questioned

News Daily News

Déjà Vu All Over Again? Results of Intracoronary Stem Cell Study Questioned

Yael L. Maxwell

November 13, 2025

Lower Mortality With Complete Revascularization in Acute MI Patients With MVD

News Conference News AHA 2025

Lower Mortality With Complete Revascularization in Acute MI Patients With MVD

Michael O'Riordan

November 12, 2025

CELEBRATE: Zalunfiban, a Novel Glycoprotein IIb/IIIa Inhibitor, Helps in STEMI

News Conference News AHA 2025

CELEBRATE: Zalunfiban, a Novel Glycoprotein IIb/IIIa Inhibitor, Helps in STEMI

Michael O'Riordan

November 11, 2025

AI-Powered Digital Stethoscope Detects Low EF in Patients With HF Symptoms

News Conference News AHA 2025

AI-Powered Digital Stethoscope Detects Low EF in Patients With HF Symptoms

November 10, 2025

Fish Oil Halves CV Risk in Patients on Dialysis: PISCES

News Daily News

Fish Oil Halves CV Risk in Patients on Dialysis: PISCES

Yael L. Maxwell

November 10, 2025

Anticoagulation Alone Is Best in AF Patients a Year or More Out From PCI

News Conference News AHA 2025

Anticoagulation Alone Is Best in AF Patients a Year or More Out From PCI

November 09, 2025

Stopping DOACs After Successful AF Ablation Feasible in Low-risk Patients: OCEAN

News Conference News AHA 2025

Stopping DOACs After Successful AF Ablation Feasible in Low-risk Patients: OCEAN

Michael O'Riordan

November 08, 2025

Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV

News Conference News AHA 2025

Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV

Michael O'Riordan

November 08, 2025

ENGULF Novel PE Thrombectomy Device Minimizes Blood Loss

News Conference News VIVA 2025

ENGULF Novel PE Thrombectomy Device Minimizes Blood Loss

November 07, 2025

PREVENT-TAHA8: Post-MI Intracoronary Stem Cells May Lower HF Risk After STEMI

News Daily News

PREVENT-TAHA8: Post-MI Intracoronary Stem Cells May Lower HF Risk After STEMI

November 04, 2025

DOAC May Be Safer Than DAPT After Left Atrial Appendage Closure ANDES

News Conference News TCT 2025

DOAC May Be Safer Than DAPT After Left Atrial Appendage Closure: ANDES

Yael L. Maxwell

November 04, 2025

Cardiologists Saw Rising Incomes but Additional Pressures in 2024: MedAxiom

News Daily News

Cardiologists Saw Rising Incomes but Additional Pressures in 2024: MedAxiom

October 30, 2025

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.